TEVA PHARMACEUTICAL INDUSTRIES LTD Quarterly Other Liabilities, Noncurrent in USD from Q4 2010 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.
Summary
Teva Pharmaceutical Industries Ltd quarterly Other Liabilities, Noncurrent history and growth rate from Q4 2010 to Q3 2024.
  • Teva Pharmaceutical Industries Ltd Other Liabilities, Noncurrent for the quarter ending September 30, 2024 was $4.34B, a 9.98% increase year-over-year.
Other Liabilities, Noncurrent, Quarterly (USD)
Other Liabilities, Noncurrent, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q3 2024 $4.34B +$394M +9.98% Sep 30, 2024 10-Q 2024-11-06
Q2 2024 $4.36B +$262M +6.4% Jun 30, 2024 10-Q 2024-07-31
Q1 2024 $3.99B +$9M +0.23% Mar 31, 2024 10-Q 2024-05-08
Q4 2023 $4.02B +$74M +1.88% Dec 31, 2023 10-Q 2024-11-06
Q3 2023 $3.95B +$91M +2.36% Sep 30, 2023 10-Q 2024-11-06
Q2 2023 $4.09B +$234M +6.06% Jun 30, 2023 10-Q 2024-07-31
Q1 2023 $3.98B +$694M +21.1% Mar 31, 2023 10-K 2024-02-12
Q4 2022 $3.95B +$1.37B +53% Dec 31, 2022 10-K 2024-02-12
Q3 2022 $3.86B +$1.66B +75.2% Sep 30, 2022 10-K 2024-02-12
Q2 2022 $3.86B +$1.65B +74.3% Jun 30, 2022 10-K 2024-02-12
Q1 2022 $3.29B +$1.07B +48.1% Mar 31, 2022 10-Q 2022-05-03
Q4 2021 $2.58B +$338M +15.1% Dec 31, 2021 10-K 2023-02-10
Q3 2021 $2.2B +$22M +1.01% Sep 30, 2021 10-Q 2021-10-27
Q2 2021 $2.22B -$196M -8.13% Jun 30, 2021 10-Q 2021-07-28
Q1 2021 $2.22B -$404M -15.4% Mar 31, 2021 10-Q 2021-04-28
Q4 2020 $2.24B -$400M -15.2% Dec 31, 2020 10-K 2022-02-09
Q3 2020 $2.18B -$365M -14.3% Sep 30, 2020 10-Q 2020-11-05
Q2 2020 $2.41B +$769M +46.8% Jun 30, 2020 10-Q 2020-08-05
Q1 2020 $2.62B +$955M +57.2% Mar 31, 2020 10-Q 2020-05-07
Q4 2019 $2.64B +$913M +52.9% Dec 31, 2019 10-K 2021-02-10
Q3 2019 $2.55B +$743M +41.2% Sep 30, 2019 10-Q 2019-11-07
Q2 2019 $1.64B -$172M -9.48% Jun 30, 2019 10-Q 2019-08-07
Q1 2019 $1.67B -$206M -11% Mar 31, 2019 10-Q 2019-05-02
Q4 2018 $1.73B -$116M -6.29% Dec 31, 2018 10-K 2020-02-21
Q3 2018 $1.8B -$156M -7.96% Sep 30, 2018 10-Q 2018-11-01
Q2 2018 $1.81B -$224M -11% Jun 30, 2018 10-Q 2018-08-02
Q1 2018 $1.88B +$232M +14.1% Mar 31, 2018 10-Q 2018-05-03
Q4 2017 $1.84B +$204M +12.4% Dec 31, 2017 10-K 2019-02-19
Q3 2017 $1.96B +$567M +40.7% Sep 30, 2017 6-K 2017-11-02
Q2 2017 $2.04B +$685M +50.6% Jun 30, 2017 6-K 2017-08-03
Q1 2017 $1.64B +$330M +25.1% Mar 31, 2017 6-K 2017-05-11
Q4 2016 $1.64B +$444M +37.2% Dec 31, 2016 10-K 2018-02-12
Q3 2016 $1.39B +$70M +5.3% Sep 30, 2016 6-K 2016-11-15
Q2 2016 $1.35B +$12M +0.9% Jun 30, 2016 6-K 2016-08-04
Q1 2016 $1.31B -$59M -4.3% Mar 31, 2016 6-K 2016-05-09
Q4 2015 $1.2B +$86M +7.76% Dec 31, 2015 20-F 2017-02-15
Q3 2015 $1.32B +$100M +8.18% Sep 30, 2015 6-K 2015-10-29
Q2 2015 $1.34B +$341M +34.1% Jun 30, 2015 6-K 2015-07-30
Q1 2015 $1.37B +$412M +42.9% Mar 31, 2015 6-K 2015-04-30
Q4 2014 $1.11B -$164M -12.9% Dec 31, 2014 20-F 2016-02-11
Q3 2014 $1.22B -$595M -32.7% Sep 30, 2014 6-K 2014-10-30
Q2 2014 $1B -$718M -41.8% Jun 30, 2014 6-K 2014-07-31
Q1 2014 $960M -$362M -27.4% Mar 31, 2014 6-K 2014-05-02
Q4 2013 $1.27B -$20M -1.55% Dec 31, 2013 20-F 2015-02-09
Q3 2013 $1.82B +$536M +41.8% Sep 30, 2013 6-K 2013-10-31
Q2 2013 $1.72B +$401M +30.4% Jun 30, 2013 6-K 2013-08-01
Q1 2013 $1.32B +$46M +3.61% Mar 31, 2013 6-K 2013-05-02
Q4 2012 $1.29B +$16M +1.25% Dec 31, 2012 20-F 2014-02-10
Q3 2012 $1.28B +$453M +54.7% Sep 30, 2012 6-K 2012-11-01
Q2 2012 $1.32B +$487M +58.7% Jun 30, 2012 6-K 2012-08-02
Q1 2012 $1.28B +$467M +57.7% Mar 31, 2012 6-K 2012-05-09
Q4 2011 $1.28B +$279M +28% Dec 31, 2011 20-F 2013-02-12
Q3 2011 $828M Sep 30, 2011 6-K 2011-11-02
Q2 2011 $830M Jun 30, 2011 6-K 2011-07-28
Q1 2011 $809M Mar 31, 2011 6-K 2011-05-11
Q4 2010 $998M Dec 31, 2010 20-F 2012-02-17
* An asterisk sign (*) next to the value indicates that the value is likely invalid.